Evidence map›Paper›PMID 33085031›Full record

ArticleInternational journal of hematology2020

Correction to: Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.

Sachie Kasai, Hidehiro Itonaga, Daisuke Niino, Hiroaki Miyoshi, Takeharu Kato, Daisuke Imanishi, Machiko Fujioka, Takafumi Furumoto, Shinya Sato, Yasushi Sawayama and 7 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Sachie KasaiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hidehiro ItonagaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4, Sakamoto, Nagasaki city, Nagasaki, Japan. itonaga-ngs@umin.ac.jp.ORCID http://orcid.org/0000-0003-1438-3623
Daisuke NiinoDepartment of Pathology, Sasebo City General Hospital, Sasebo, Japan.
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takeharu KatoDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Daisuke ImanishiDepartment of Hematology, Nagasaki Prefecture Gotochuoh Hospital, Goto, Japan.
Machiko FujiokaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Takafumi FurumotoDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Yasushi SawayamaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Jun TaguchiDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Tomoko HataDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4, Sakamoto, Nagasaki city, Nagasaki, Japan.
Shinichiro YoshidaDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication of the article, the authors would like to alter the color of characters in the Supplemental Table 1 and 2.

Identifiers

PMID33085031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.